Photocure ASA posted modest Q2 2026 revenue growth and stable earnings, underscoring resilient demand for its Hexvix/Cysview bladder cancer imaging agents
Executive summary: Photocure ASA announced Q2 2026 revenues of NOK 140.0 million and adjusted EBITDA of NOK 27.2 million, reflecting modest year‑over-year growth. The figures show sustained demand for Photocure’s Hexvix/Cysview products, providing the company with reliable cash flow to support potential R&D or shareholder returns.
Who is involved: Photocure ASA (OSE: PHO), its Hexvix®/Cysview® franchise, investors and analysts tracking the urology diagnostics sector.
Likely next: The firm may issue guidance for the second half of 2026 and provide updates on its product pipeline at upcoming medical conferences.
Photocure ASA reported Hexvix®/Cysview® revenues of NOK 140.0 million for Q2 2026, up 3.2% from NOK 135.6 million in the same quarter of 2025. Adjusted EBITDA was NOK 27.2 million, slightly above the NOK 27.0 million recorded a year earlier. The results indicate steady performance in the company’s niche urology imaging market.
Timeline
- — Photocure ASA: Results for the second quarter of 2026 (PR Newswire)
Analysis — what this means
Sectors affected
- Urology diagnostics
- Bladder cancer imaging
Key entities
Sources
- Photocure ASA: Results for the second quarter of 2026 — PR Newswire